Core Viewpoint - The National Health Commission of China emphasizes the importance of vaccination for adults, providing guidance on how to choose appropriate vaccines based on various factors such as age, health status, and travel plans [1][2]. Group 1: Types of Vaccines - There are several types of vaccines available for adults in China, including those for respiratory infectious diseases (influenza, pneumococcal, COVID-19, measles-mumps-rubella), intestinal infectious diseases (hepatitis A, hepatitis E, cholera), and zoonotic diseases (rabies, hemorrhagic fever, Japanese encephalitis) [1]. - Vaccines can be categorized into three main groups: 1. Vaccines recommended for all adults except those with contraindications, such as the influenza vaccine, which is advised for everyone regardless of previous vaccination history [1]. 2. Vaccines primarily recommended for specific high-risk groups, including hepatitis E for chronic liver disease patients, women of childbearing age, the elderly, students, military personnel, food service workers, livestock farmers, and travelers to endemic areas [1]. 3. Vaccines for specific situations, such as rabies vaccine after animal bites, and other vaccines based on travel requirements [2]. Group 2: Factors for Vaccine Selection - Adults should consider multiple factors when selecting vaccines, including age, health condition, occupation, travel plans, and vaccination history [2]. - It is recommended to consult local disease control centers or vaccination units for personalized advice on vaccine selection [2].

Core Viewpoint - The prevalence of viral hepatitis in Shandong has significantly decreased, with the hepatitis B surface antigen positivity rate dropping to 2.25%, and the rate among children under 5 years old falling from 8% in 1992 to 0.03% currently [1][2] Group 1: Vaccination Efforts - The province has implemented a comprehensive prevention strategy focusing on vaccination, with 2.6214 million doses of hepatitis A and B vaccines administered to eligible children in 2024, achieving a full vaccination rate of over 95% [1] - Since 1992, hepatitis B vaccination has been promoted among newborns, and since 2002, it has been included in the children's immunization program, provided free of charge [1] - In 2011, the province began providing free hepatitis B immunoglobulin to newborns of hepatitis B surface antigen-positive mothers to further prevent mother-to-child transmission [1] Group 2: Monitoring and Public Health Initiatives - A robust epidemic reporting system has been established, with viral hepatitis cases reported within 24 hours of diagnosis since 2004 [2] - The province has launched a three-year action plan (2023-2025) to eliminate the public health threat of hepatitis B, implementing strong public health interventions and promoting safe drinking water [2] - Ongoing efforts include monitoring susceptible populations and standardizing patient management to prevent mother-to-child transmission of hepatitis B [2]

Core Viewpoint - WanTai Biologics (603392.SH) reported a significant decline in performance, with a 91.49% drop in net profit for 2024, attributed to challenges in the vaccine sector, including competition and government procurement impacts [1][2][9]. Financial Performance - For 2024, WanTai Biologics reported total revenue of 2.245 billion yuan, a decrease of 59.25% compared to 2023, and a net profit of 106 million yuan, down 91.49% year-on-year [2][3]. - The company recorded a non-recurring net profit of -186 million yuan, reflecting a change of -117.29% year-on-year [2][3]. - In the first quarter of 2025, the company continued to experience a downward trend, with revenue of 401 million yuan, a decline of 4.76%, and a net loss of 52.78 million yuan, marking a 141.98% decrease year-on-year [2][3]. Vaccine Sector Challenges - The decline in performance is primarily due to the vaccine segment facing market adjustments, government procurement pressures, and competition from domestic rivals [9][20]. - The price of the company's bivalent HPV vaccine has been under pressure, with the bidding price range dropping from 329-344 yuan per bottle in 2020-2022 to 63-344 yuan in 2024 [20][21]. - The company’s vaccine sales have significantly decreased, with inventory levels showing a substantial drop in production and sales compared to previous years [24][25]. Clinical Development and Market Position - WanTai Biologics is advancing its nine-valent HPV vaccine, which is currently in Phase III clinical trials, with plans for commercialization pending regulatory approval [16][19]. - The company has developed the first domestic bivalent HPV vaccine, which has gained market access in China and 21 other countries [9][12]. - The competitive landscape is intensifying, with other companies like Watson Bio also entering the HPV vaccine market, further impacting WanTai's market share [20][19]. Future Outlook - The company is focusing on its in vitro diagnostic business, which has shown more stability compared to the vaccine sector, and has appointed a new general manager with extensive experience in diagnostics [25].

万泰生物（603392）近日发布的年报显示，2024年公司营业收入为22.45亿元，同比下降59.25%；归属 于上市公司股东的净利润为1.06亿元，同比下降91.49%。此次万泰生物2024年的营收、净利润均创公司 上市5年来新低。 九价HPV疫苗面临竞争压力 2024年，万泰生物体外诊断板块实现营收16.09亿元，同比增长4.91%。不难看出，体外诊断收入微弱的 增势，在短时间内无法弥补疫苗销售收入的下降。 业绩承压下，部分投资者将希望寄托在万泰生物的九价HPV疫苗上。但目前九价HPV疫苗的市场竞争激 烈，HPV疫苗市场需求放缓，且其他企业的研发进展较快，万泰生物九价产品的优势并不明朗。 疫苗板块收入下降 万泰生物的业务主要涉及体外诊断及疫苗两大领域。其中，体外诊断产品涉及新冠、肿瘤标志物、肝 炎、艾滋病等疾病的体外诊断试剂及诊断仪器；疫苗业务主要有戊肝疫苗、二价HPV疫苗和鼻喷新冠疫 苗。 新京报记者注意到，此次万泰生物2024年的营收、净利润均创公司上市5年来新低，净利润更是回到了 10年前。数据显示，2020年至2023年，万泰生物实现营业收入分别为23.54亿元、57.50亿元、111.9亿 元、 ...

3、公司全体董事出席董事会会议。 登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：603392 公司简称：万泰生物 4、容诚会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到http://www.sse.com.cn网站仔细阅读年度报告全文。 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 经容诚会计师事务所（特殊普通合伙）审计，2024年度，公司母公司报表实现归属于母公司股东的净利 润338,693,382.81元，合并报表实现归属于上市公司股东的净利润106,235,425.64元。截至2024年12月31 日，公司期末可供分配利润为1,733,387,095.92元。 经公司第六届董事会第七次会议审议通过，在综合考虑公司的实际经营发展情况和资金需求，以及公司 长期发展规划的情况下， ...